Teacher Retirement System of Texas Boosts Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Teacher Retirement System of Texas raised its position in Moderna, Inc. (NASDAQ:MRNA) by 14.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 101,382 shares of the company’s stock after buying an additional 12,651 shares during the period. Teacher Retirement System of Texas’ holdings in Moderna were worth $4,215,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of MRNA. Privium Fund Management B.V. boosted its position in Moderna by 103.7% during the fourth quarter. Privium Fund Management B.V. now owns 82,476 shares of the company’s stock worth $3,429,000 after acquiring an additional 41,994 shares during the last quarter. Signaturefd LLC boosted its holdings in shares of Moderna by 17.4% during the fourth quarter. Signaturefd LLC now owns 3,618 shares of the company’s stock worth $150,000 after purchasing an additional 535 shares during the last quarter. CBIZ Investment Advisory Services LLC grew its position in shares of Moderna by 4,400.0% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 1,125 shares of the company’s stock valued at $47,000 after purchasing an additional 1,100 shares during the period. Catalyst Funds Management Pty Ltd acquired a new position in Moderna in the fourth quarter valued at $1,464,000. Finally, Intact Investment Management Inc. purchased a new position in Moderna during the fourth quarter worth about $420,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Up 4.6 %

Shares of MRNA opened at $34.17 on Tuesday. The firm has a market cap of $13.21 billion, a price-to-earnings ratio of -3.68 and a beta of 1.86. The business’s 50 day moving average is $34.89 and its two-hundred day moving average is $45.39. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47.

Analyst Upgrades and Downgrades

MRNA has been the subject of a number of research analyst reports. Morgan Stanley dropped their price objective on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 15th. Citigroup assumed coverage on shares of Moderna in a research note on Thursday, March 13th. They set a “neutral” rating and a $40.00 price target on the stock. Royal Bank of Canada reissued a “sector perform” rating and set a $40.00 price objective on shares of Moderna in a research note on Tuesday, February 18th. Evercore ISI set a $50.00 price objective on Moderna in a report on Friday, February 14th. Finally, UBS Group reduced their target price on Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a report on Wednesday, February 19th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $59.00.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.